Psychiatric Problems in Children and Adolescents Infected With HIV at Birth
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00100542 |
Recruitment Status
:
Completed
First Posted
: January 4, 2005
Last Update Posted
: January 21, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HIV Infections Mental Disorders | Behavioral: Psychiatric interviews |
Research has shown that HIV is able to penetrate the blood-brain barrier and may significantly affect the central nervous system (CNS). Although the effects of HIV on the CNS are not fully understood, there is growing evidence that the effects are psychosocial in nature; HIV infected children experience higher rates of psychiatric symptoms and hospitalizations than their uninfected counterparts. Confounding the HIV CNS relationship is evidence suggesting that the CNS effects of HIV may also be related to antiretroviral treatment. This study will examine the rates and severity of psychiatric symptoms in both HIV infected and uninfected children and adolescents. In addition, this study will determine the relationship between duration of antiretroviral treatment and psychiatric symptoms.
No treatment will be given as part of this study. The study will last for 96 weeks and be divided into two parts. In Part 1, HIV infected and uninfected participants and their caregivers will complete a series of measures and questionnaires regarding mental health, pain, and adherence to treatment. In Part 2, all participants and their caregivers will complete a subset of the original measures at Weeks 48 and 96. This follow-up part of the study will assess any long-term changes in psychiatric symptoms. In addition, a subset of HIV infected and uninfected participants and their caregivers will take part in psychiatric interviews at specified study sites. A portion of these interviews will be audio-taped.
Study Type : | Observational |
Estimated Enrollment : | 800 participants |
Observational Model: | Case Control |
Time Perspective: | Prospective |
Official Title: | Psychiatric Co-Morbidity in Perinatally HIV-Infected Children and Adolescents |
Study Start Date : | April 2005 |
Actual Primary Completion Date : | September 2006 |
Actual Study Completion Date : | September 2006 |

Group/Cohort | Intervention/treatment |
---|---|
1
All HIV infected and uninfected participants and their caregivers.
|
Behavioral: Psychiatric interviews
Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria for HIV Infected Participants:
- Acquired HIV through mother-to-child transmission
Inclusion Criteria for HIV Uninfected Participants:
- HIV uninfected
Inclusion Criteria for All Participants:
- Living with same parent or primary caregiver for at least 12 months prior to study screening
- Willing and able to provide consent or assent
Exclusion Criteria for HIV Infected Participants:
- Acquired HIV through adult high-risk behavior, blood transfusion, or abuse
Exclusion Criteria for All Participants:
- IQ of 69 or lower, for participants whose primary language is English. More information on this criterion can be found in the protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00100542

Study Chair: | Sharon Nachman, MD | Department of Pediatrics, Stony Brook University |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Wende Levy, IMPAACT |
ClinicalTrials.gov Identifier: | NCT00100542 History of Changes |
Other Study ID Numbers: |
PACTG P1055 U01AI068632 ( U.S. NIH Grant/Contract ) |
First Posted: | January 4, 2005 Key Record Dates |
Last Update Posted: | January 21, 2011 |
Last Verified: | January 2011 |
Keywords provided by International Maternal Pediatric Adolescent AIDS Clinical Trials Group:
Treatment Experienced Treatment Naive Psychopathology |
Anti-Retroviral Agents Child Adolescent |
Additional relevant MeSH terms:
HIV Infections Mental Disorders Psychotic Disorders Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Schizophrenia Spectrum and Other Psychotic Disorders |